Trial site
Wichita Urology Group
Wichita, Kansas 67226, United StatesNot linked to an institution yet
- 13running trials
- 1closed trial
The trials here
What the 14 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 22 trials
- Phase 11 trial
- Phase 2/31 trial
- Status
- Active, not recruiting7 trials
- Recruiting6 trials
- Completed1 trial
- Lead sponsor
- Janssen Research & Development, LLC4 trials
- CG Oncology, Inc.2 trials
- Ferring Pharmaceuticals2 trials
- Astellas Pharma Global Development, Inc.1 trial
- Bayer1 trial
- and 4 more
Running trials
Recruiting
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
NCT06545955· Phase 3· Ferring Pharmaceuticals· Source
Contact: Ferring Pharmaceuticals
Recruiting
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06510374· Phase 3· Ferring Pharmaceuticals· Source
Contact: Ferring Pharmaceuticals
Recruiting
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
NCT06567743· Phase 2· CG Oncology, Inc.· Source
Contact: Philippe Nabbout, MD
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
NCT06056830· Phase 3· Clarity Pharmaceuticals Ltd· Source
Contact: Timothy Richardson, MD
Active, not recruiting
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235· Phase 3· CG Oncology, Inc.· Source
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
NCT05491525· Phase 2/3· Urovant Sciences GmbH· Source
Contact: Kahlil N Saad (principal investigator)
Active, not recruiting
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
NCT05243550· Phase 3· UroGen Pharma Ltd.· Source
Recruiting
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
NCT04729114· Phase 1· Astellas Pharma Global Development, Inc.· Source
Contact: Astellas Pharma Global Development, Inc.
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described
NCT04122976· Bayer· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error